Kurzfassung

A multicenter, double-blind and open-label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate o severe chronic plaque-type psoriasis treated with either a fixed dose regimen or on a retreatment at start of relapse regimen.